Immune Checkpoint Inhibition in Head and Neck Cancer.

Front Oncol · 2018 · PMC6123367 · PMID 30211111

Europe PMC DOI

hedged sentence

0.0200

closest p · 0.4× alpha

0.0200

boldest claim

The sentences

did not reach statistical significancep = 0.020actually significant

It demonstrated a median OS of 8.4 months with pembrolizumab compared to 7.1 months in the control arm, with a hazard ratio of 0.81 (95% confidence interval 0.66–0.99), which did not reach statistical significance ( p = 0.020) within the multiplicity statistical model.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.